UX003: Clinical Trials

2 trials of UX003, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Completed 2
Phase 11Completed 1

Follow UX003: new trials by email Literature Review of UX003 trials Research Report on UX003

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age
UX003 - Sly Syndrome, MPS VII
Phase 2CompletedUltragenyx Pharmaceutical Inc82015-07-212019-10-30
An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
UX003 - Mucopolysaccharidosis Type 7
Phase 1 / Phase 2CompletedUltragenyx Pharmaceutical Inc32013-11-012019-01-04

Conditions studied

Lysosomal Storage Diseases (2)  ·  Metabolic Diseases (2)  ·  Mucopolysaccharidosis VII (2)  ·  Rare Diseases (2)  ·  Mucopolysaccharidoses (1)

Sponsors

Ultragenyx Pharmaceutical Inc (2)

Countries

Portugal (1)  ·  Spain (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Simon Jones, MD (1)

Results publications

PMID 30467742, PMID 35331634, PMID 37415957

NIH funding

2015 (1)